Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases
TSOI products = 12 - 5 Biologics, 6 Nutraceuticals, 1 Pharmaceutical
TSOI nutraceutical products released from granted patent
Projuvenol, NanoStilbene, DermalStilbene, IsoStilbene, NeuroStilbene, Alpha Lipoic Acid
4 TSOI nutraceutical products for sale online
Projuvenol, Nanostilbene, DermalStilbene, NeuroStilbene
5 Biologics, 1 Pharmaceutical licensed to Pan Am Cancer Treatment Center in Mexico
Pan Am Cancer Treatment Center Introductory Video
StemVacs Phase 1 clinical trials @ Pan Am Cancer Treatment Center in Mexico
for TSOI Right To Try Clinic future opening in USA .
Pilot pharmacokinetic trial of NanoStilbene for dosage /efficacy
Wes Chandler to Lead on CTE
Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries
A small pilot study is in the planning stages to be performed under the direction of Dr. Santosh Kesari at John Wayne Cancer Institute in Santa Monica CA. by conducting a clinical trial assessing the effects of pterostilbene in modulating immune response and inflammatory parameters in a group of advanced solid tumor cancer patients.
A small pilot study is in the planning stages to be performed under the direction of Dr. Nassir Azimi in San Diego CA. by conducting a study using NanoStilbene in a group of heart attack patients :
TSOI patent portfolio
AS - 1.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
IO - 918,152,752
Restricted - 784,040,972
Unrestricted - 134,111,780
Float - 70,343,547
SEC Filings :https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany
TSOI PR History 5/1- 9/4/18
Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients
Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's
Right to Try Law
Oceanside, CA -- September 04, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today completion of a Phase I clinical trial in advanced cancer patients using its StemVacs cellular immunotherapy. The clinical trial was aimed at establishing the safety of StemVacs, an immunotherapeutic cell-based drug that instructs the immune system to seek and destroy cancer stem cells. It is believed that cancer stem cells are responsible for initiating the growth of tumors.
"Through our collaborators at the Pan Am Cancer Treatment Centers, we have been able to successfully administer the StemVacs cellular cancer immunotherapeutic to 10 patients with various types of advanced cancers. We have observed no treatment-associated adverse events, and in some cases, stabilization of tumors and stimulation of immunity were observed and noted" said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "This Phase I safety data strongly supports our continued clinical development of StemVacs, of which part of the development pathway includes providing patients access to it now under the Right to Try Law."
Dendritic cells (DC), which are the main ingredient in StemVacs, are cells of the immune system whose primary function is to initiate immune responses against different pathogens (1,2). In the context of cancer, DC's activate immune responses that in some cases are capable of killing cancer cells (3,4). Unfortunately, in cancer patients, many times the dendritic cells are not functionally active (5-7). This is because cancer cells produce factors such as VEGF, which inhibit the ability of the DC to perform their job of activating T cells (8,9). The StemVacs product is comprised of DC that are generated under laboratory conditions so as to render them resistant to the inhibitory effects of cancer. Additionally, the StemVacs DC's are designed so as to induce an immune response against cancer stem cells.
"Immunotherapy is the greatest advancement in the area of clinical oncology. FDA approved immunotherapies include the DC based product Provenge, the T cell based products Yescarta and Kymriah, and antibody based therapies such as Opdivo and Keytruda" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "To our knowledge, StemVacs is the only clinical stage immunotherapeutic that kills cancer stem cells. This, combined with the safety and signals of efficacy obtained from the current Phase I clinical trial, support us to expand the use of StemVacs under President Trump's recently passed Right to Try Law."
E Commerce Site
TSOI on Facebook
TSOI on Twitter